Bayesian Capital Management, LP Coherus Bio Sciences, Inc. Transaction History
Bayesian Capital Management, LP
- $788 Million
- Q4 2024
A detailed history of Bayesian Capital Management, LP transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 14,100 shares of CHRS stock, worth $12,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,100Holding current value
$12,549% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding CHRS
# of Institutions
130Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$9.93 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$4.7 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$4.68 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$3.25 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $69.2M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...